Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (Paulo Brofman)
- Development stage
- Unknown
- Lead developer
- Pontifícia Universidade Católica do Paraná
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
Umbilical cord mesenchymal stem cells (UC-MSCs) are a specific type of multipotent cell therapy being developed by Paulo Brofman and researchers at the Pontifícia Universidade Católica do Paraná (PUCPR) for the treatment of severe COVID-19 pneumonia. These cells are harvested from the umbilical cord tissue and expanded in vitro before being administered intravenously to patients. The therapeutic rationale is based on the cells' ability to home to sites of inflammation, particularly the lungs, where they release a variety of anti-inflammatory cytokines and growth factors. This paracrine activity helps to dampen the 'cytokine storm' associated with severe SARS-CoV-2 infection, reduce alveolar damage, and potentially accelerate the recovery of lung function. The product is currently being evaluated in Phase I/IIa clinical trials to assess its safety and preliminary efficacy in hospitalized patients requiring respiratory support.
- Other names
- umbilical cord mesenchymal stromal cellsUC-MSCsMesenchymal stem cell
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (Paulo Brofman).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Paulo Brofman).